Repros Therapeutics reports six month Androxal data


Repros Therapeutics (RPRX) reports six-month interim results from a study of "Androxal treatment of secondary hypogonadal men and its effect on bone mineral density."

No bone loss was observed compared to placebo.

Some improvement in bone mineral density was observed in the Androxal group.

Topline, 12-month results are due in Q2 2014. (PR)

Shares +0.9% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs